Articles from APA

Primary tabs

Trippy depression treatment? Hopes and hype for ketamine - ABC ... - ABC News

Submitted by Anonymous (not verified) on Wed, 10/31/2018 - 05:03

Trippy depression treatment? Hopes and hype for ketamine - ABC ...ABC NewsGet breaking national and world news, broadcast video coverage, and exclusive interviews.

Combination drug targeting opioid system may help relieve symptoms of major depression - MD Linx

Submitted by Anonymous (not verified) on Tue, 10/30/2018 - 14:33

Combination drug targeting opioid system may help relieve symptoms of major depressionMD LinxInterim data from that study were presented at the American Psychiatric Association annual meeting in May 2018.

Combination drug targeting opioid system may help relieve symptoms of major depression - MD Linx

Submitted by Anonymous (not verified) on Tue, 10/30/2018 - 14:31

Combination drug targeting opioid system may help relieve symptoms of major depressionMD LinxInterim data from that study were presented at the American Psychiatric Association annual meeting in May 2018.

Combination drug targeting opioid system may help relieve symptoms of major depression - MD Linx

Submitted by Anonymous (not verified) on Tue, 10/30/2018 - 14:26

Combination drug targeting opioid system may help relieve symptoms of major depressionMD LinxInterim data from that study were presented at the American Psychiatric Association annual meeting in May 2018.

Alkermes stock drops 6.5% after FDA briefing documents raise questions about depression drug - MarketWatch

Submitted by Anonymous (not verified) on Tue, 10/30/2018 - 13:01

Alkermes stock drops 6.5% after FDA briefing documents raise questions about depression drugMarketWatchThe drug is intended for major depressive disorder, also called depression, which affects an estimated one in 15 adults in any given year, ac

Party-Drug-Turned-Antidepressant Approaches Approval - Scientific American

Submitted by Anonymous (not verified) on Tue, 10/30/2018 - 07:00

Party-Drug-Turned-Antidepressant Approaches Approval  Scientific AmericanJohnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don't understand how the fast-acting antidepressant lifts moods.

Pages